Adam M. Brufsky, MD, PhD, discusses the utility of trastuzumab biosimilars in breast cancer.
Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh Medical Center Hillman Cancer Center, discusses the utility of trastuzumab (Herceptin) biosimilars in breast cancer.
Currently, 5 trastuzumab biosimilars have been approved by the FDA for use in HER2-positive breast cancer.
There may be subtle differences among the individual agents; however, the drugs should be considered the same, says Brufsky.
Selecting the optimal agent will ultimately come down to availability and cost rather than medical factors, he concludes.